24 repeat units for recognition of a specific set of 24 contiguous nucleotides at the target sites (Supplementary Fig. 1 ).
For each pair of TALEN genes, one TALEN gene (half of the pair) was under the control of the 35S promoter of cauliflower mosaic virus and the other gene was driven by the maize ubiquitin 1 promoter, comprising a specific TALEN pair in a single plasmid (Supplementary Fig. 2 ). Each plasmid also contained a marker gene for hygromycin resistance. These constructs were introduced pathogen's nutritional needs and enhance its persistence 2, 14 . The Os11N3 promoter contains an effector-binding element (EBE) for AvrXa7, overlapping with another EBE for PthXo3 and with the TATA box ( Fig. 1a and Supplementary Fig. 1 ). We deployed two pairs of designer TALENs (pair 1 and pair 2) independently to induce mutations in these overlapping EBEs of the Os11N3 promoter and thus to interfere with the virulence function of AvrXa7 and PthXo3, but not the developmental function of Os11N3 (Supplementary Fig. 1 and Supplementary Note). The TALE repetitive regions used for nuclease fusions included the native AvrXa7 and three designer TALE repetitive regions custom synthesized using a modular assembly method 8 .
Each designer TALEN contained
To the Editor: Transcription activator-like (TAL) effectors of Xanthomonas oryzae pv. oryzae (Xoo) contribute to pathogen virulence by transcriptionally activating specific rice disease-susceptibility (S) genes 1,2 . TAL effector nucleases (TALENs)-fusion proteins derived from the DNA recognition repeats of native or customized TAL effectors and the DNA cleavage domains of FokI 3-5 -have been used to create site-specific gene modifications in plant cells 6, 7 , yeast 8 , animals [9] [10] [11] [12] and even human pluripotent cells 13 . Here, we exploit TALEN technology to edit a specific S gene in rice to thwart the virulence strategy of X. oryzae and thereby engineer heritable genome modifications for resistance to bacterial blight, a devastating disease in a crop that feeds half of the world's population.
We targeted the rice bacterial blight susceptibility gene Os11N3 (also called OsSWEET14) for TALEN-based disruption. This rice gene encodes a member of the SWEET sucrose-efflux transporter family and is hijacked by X. oryzae pv. oryzae, using its endogenous TAL effectors AvrXa7 or PthXo3, to activate the gene and thus divert sugars from the plant cell so as to satisfy the High-efficiency TALEN-based gene editing produces disease-resistant rice
Os11N3

AvrXa7 EBE PthXo3 EBE TATA box directed mutations, we investigated whether the pathogenic strain of Xoo that is dependent on AvrXa7 or PthXo3 for virulence is able to either induce the modified Os11N3 gene in homozygous T 2 plants or cause disease. The modified Os11N3 gene was no longer inducible by AvrXa7 or PthXo3 delivered by the pathogenic strain of the bacterium (ME2(avrXa7) or ME2(pthXo3)) in T 2 plants homozygous for either the 9-, 6-, 15-or 4-bp deletion (Fig. 1f for AvrXa7, Supplementary  Fig. 8a for PthXo3). The loss of induction was specific to Os11N3, as the induction of Os04g19960, a transposon coding gene collaterally targeted by AvrXa7, was not prevented (Fig. 1g) . Similarly, the induction of another S gene (Os8N3, also known as OsSWEET11) by PthXo1 in the T 2 mutant plants remained unaffected ( Supplementary  Fig. 8b ). These TALEN-modified T 2 plants also showed strong resistance to infection of the AvrXa7-or PthXo3-dependent Xoo strains but not the PthXo1-dependent pathogenic Xoo strain as determined from symptoms ( Fig. 1h for AvrXa7) and by quantitative measurement of the lengths of leaf lesions in a standard pathogenesis assay described in Supplementary Methods (Supplementary Fig. 9 ).
We also investigated the possibility of using genetic segregation to obtain genetically modified rice lacking any selection marker and TALEN gene. The PCR assay using primers for amplification of the hygromycin resistance gene and for amplification of the TALEN genes failed to detect the presence of either gene in 5 out of 37 T 1 plants that contained the desired genetic modifications in the Os11N3 promoter and that were disease resistant (Supplementary Fig. 10 ). Although these data clearly demonstrate the absence of intact TALEN and hygromycin-resistance genes, further sequencing of the genomes of several mutants and the Kitake parental line will be needed to conclusively demonstrate that all of the transgene fragments have been removed.
The rice Os11N3 gene is induced by 32 of 40 Xoo strains collected worldwide (T. Li and B. Yang, unpublished data). However, polymorphisms in the Os11N3 gene that prevent induction by AvrXa7-and/or PthXo3-dependent Xoo strains and also confer disease resistance have not been identified in rice germplasm. The approaches described here for precisely and efficiently editing the disease susceptibility elements in Os11N3 and for the subsequent removal of transfer DNA (T-DNA) sequences by classic genetics likely can be applied directly to elite rice varieties to simultaneously or sequentially edit multiple into rice embryonic cells using Agrobacterium tumefaciens, and individual transformant cells were selected, propagated and regenerated into whole plants (T 0 ). The Os11N3 promoter regions from a number of independent hygromycin-resistant callus lines and the segregating progeny (T 1 ) of self-pollinated T 0 plants were amplified using the polymerase chain reaction (PCR) and sequenced to detect potential sequence alterations. For TALEN pair 1 genes, two of five examined callus lines contained biallelic mutations (Supplementary Fig. 3) . Of 23 randomly selected T 1 progeny produced from self-pollination of 7 independent T 0 plants transformed with TALEN pair 1 genes, about half (48%) carried mono-or biallelic mutations (including the four mutations detected in the two previously examined callus lines; Fig. 1b) . Approximately twothirds (63%) of the randomly selected T 1 plants (n = 30) generated from selfpollination of 66 independent T 0 plants from the two independent transformation experiments carried mutations that were induced by the TALEN pair 2 genes (Fig. 1c,d) . In total, 16 distinct mutations, including 6 that were homozygous, were detected in 53 T 1 plants from TALEN pair 1 and pair 2. The majority of these mutations were small deletions that left the TATA box intact, with the exception of two deletions in heterozygous lines that also contained a wild-type allele ( Fig. 1e and Supplementary Fig. 4 ). Bacterial infection assays using the leaf-tip clipping method on other T 1 plants (n = 627) generated from TALEN pair 2 (experiment 1) and not previously genotyped demonstrated that approximately 48% of the treated plants showed resistance to infection by pathogenic Xoo as evidenced by the length of leaf lesions (1-4 cm for resistance versus 10-14 cm for susceptibility; Supplementary Fig. 5 ). DNA sequence analyses of 27 such Xoo-resistant T 1 plants confirmed the presence of homozygous monoallelic or heterozygous biallelic EBE mutations and revealed 17 additional, distinct mutant haplotypes (Supplementary Fig. 6 ). All mutant plants were morphologically normal compared to wild-type plants, indicating that the developmental function of Os11N3 was not disrupted.
Forty plants from the second generation (T 2 ) of three self-pollinated T 1 plants were also genotyped by sequencing to determine the heritability of three TALEN-generated mutations, all of which, whether homozygous or heterozygous, were passed on to T 2 plants (Supplementary Fig. 7) .
To determine the effects of TALEN- 
How Europe's ethical divide looms over biotech law and patents
To the Editor:
The recent decision of the Court of Justice of the European Union (CJEU; Luxembourg) on stem cell patents startled the scientific community, and the role of the nongovernmental organization Greenpeace (Germany) in this process has raised eyebrows. Indeed, more shocks of this kind can be expected in the future, as political factions capitalize on the ambiguities and tensions written into the European Union's (EU; Brussels) Biotechnology Directive of 1998 (ref. 1) and into the ethics and public morality provisions of the European Patent Convention. The CJEU's decision reminds us that patent prosecution in Europe involves more than the application of technical criteria. As the European Patent Office (EPO) observed in 1991, with the Oncomouse patent in mind, "The granting of patents no longer depends on purely technical considerations; from now, applications will have to bear scrutiny in respect of their wider social implications" 2 . The CJEU's decision on stem cell patents tried to avoid these ethical and social considerations by adopting a particular interpretation of the relevant legislation.
First, it took note of the specificity of the prohibition against "the use of human embryos for industrial or commercial purposes" in article 6(2)(c) of the EU Biotechnology Directive; the CJEU thereby made a wide-ranging exploration of 'morality' or 'ordre public' unnecessary.
Second, the CJEU reached its decision that the human embryo is formed at the moment of fertilization by reference to two basic policies of the Directive-harmonization of European law and respect for human dignity. It then combined these to make its adoption of the strictest criterion seem entirely obvious. It reasoned that any uniform or 'harmonized' definition of the human embryo should be one that excluded "any possibility of patentability where respect for human dignity could thereby be affected".
In fact, the decision was not quite so straightforward. The Biotechnology Directive, on which the decision was based, embraces two ethical principles. Recital 16 affirms "fundamental principles safeguarding the dignity and integrity of the person, " whereas recital 17 declares that the patent system should encourage the production of medicines "derived from elements isolated from the human body". In affirming human dignity, the CJEU emphasized one of these principles at the expense of the other. And, in so doing, it chose to stand on one side of a divide that is deeply embedded in European culture.
This cultural tension is clearly revealed in the findings of the Eurobarometer 2010 survey on the Life Sciences and Biotechnology 3 . After receiving an introduction to regenerative medicine and stem cell research, 15,000 respondents were asked their level of agreement with the following statements: first, research involving human embryos should be forbidden, even if this means that possible treatments are not made available to ill people; second, it is ethically wrong to use human embryos in medical research even if it might offer promising new medical treatments; third, we have a duty to allow research that might lead to important new treatments, even when it involves the creation or use of human embryos; and finally, should ethical and scientific viewpoints on regenerative medicine differ, the scientific viewpoint should prevail. These questions capture two contrasting ethical principles-the sanctity or dignity of life, and the duty of care and healing-both of which feature in the Directive.
To investigate relative public support for these two ethical principles across Europe, we used latent class analysis, which assumes that respondents' answers to the set of questions reflect underlying latent classes-in this case, ethical orientations. What we find is four classes, as shown in Figure 1 .
Comparing the strong supporters (far right and far left bars), 13 countries have a majority in favor of the principle of duty of care and 13 for the principle of the sanctity of life, with 6 having roughly equal percentages of the two. Combining the strong and moderate supporters, 18 countries (including France, Italy and the UK) have a majority for the principle of duty of care, whereas 10 (including Austria, Germany and Poland) have a majority for the principle of the sanctity of life; four countries are roughly split between the two. Overall, Europe leans toward the principle of duty of care, but clearly both ethical principles find support in all countries.
Do the different ethical orientations merely reflect religious denomination? The answer is broadly no. Table 1 shows that strong support for 'sanctity of life' predominates among Muslims, whereas strong support for the 'duty of care' is more frequent among the nonreligious. By a small majority, both Catholics and Protestants support 'duty of care' . In a further analysis, we find
